Kirurgian vastuualue

Julkaisut 2011
Publications 2011

Lisätietoja julkaisusta saa klikkaamalla sen numeroa.
For full details, please click the number in front of the publication.


1 Andriole G et al. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study.
2 Atalay M et al. Treatments with sodium selenate or doxycycline offset diabetes-induced perturbations of thioredoxin-1 levels and antioxidant capacity.
3 Belch JJF et al. The Scottish-Finnish-Swedish PARTNER study of taprostene versus placebo treatment in patients with critical limb ischemia.
4 Buvat J et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study).
5 Carlsson SV et al. No excess mortality after prostate biopsy: results from the European Randomized Study of Screening for Prostate Cancer.
6 Chapple CR et al. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.
7 Cropp CD et al. Genome-wide linkage scan for prostate cancer susceptibility in Finland: evidence for a novel locus on 2q37.3 and confirmation of signal on 17q21-q22.
8 Fizazi K et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
9 Haillot O et al. The effects of combination therapy with dutasteride plus tamsulosin on clinical outcomes in men with symptomatic BPH: 4-year post hoc analysis of European men in the CombAT study.
10 Hedlund PO et al. Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer.
11 Huuskonen A et al. Common genetic variation in the IGF1 associates with maximal force output.
12 Kemppainen KJ et al. The association between antihypertensive drug use and incidence of prostate cancer in Finland: a population-based case-control study.
13 Kilpeläinen TP et al. False-positive screening results in the European randomized study of screening for prostate cancer.
14 Kokk K et al. Expression of luteinizing hormone receptors in the mouse penis.
15 Koskela VK et al. Peripheral arterial disease in octogenarians and nonagenarians: factors predicting survival.
16 Kote-jarai Z et al. Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study.
17 Kuorilehto T et al. Marfanin oireyhtymään, Ehlers-Danlosin oireyhtymään ja neurofibromatoosi 1:een liittyvät verisuonimuutokset ja niiden kirurginen hoito.
18 Mattila H et al. NMD and microRNA expression profiling of the HPCX1 locus reveal MAGEC1 as a candidate prostate cancer predisposition gene.
19 Melkas S et al. Small-vessel disease relates to poor poststroke survival in a 12-year follow-up.
20 Murtola T et al. Comparative effects of high and low-dose simvastatin on prostate epithelial cells: The role of LDL.
21 Mäkelä E et al. Magnetic resonance imaging of acute scrotum.
22 Nickel JC et al. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS).
23 Pekkarinen T et al. Aikuisen oireeton mikroskooppinen verivirtsaisuus.
24 Pogodin-Hannolainen D et al. Prostate cancer screening: a survey of attitudes and practices among Finnish physicians in 1999 and 2007.
25 Pöllänen P, Tammela T. Andrologiset lääkkeet.
26 Raitoharju E et al. miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques in the Tampere Vascular Study.
27 Raitoharju E et al. Common variation in the ADAM8 gene affects serum sADAM8 concentrations and the risk of myocardial infarction in two independent cohorts.
28 Rantanen T et al. Altered expression of HSP27 and HSP70 in distal oesophageal mucosa in patients with gastro-oesophageal reflux disease subjected to fundoplication.
29 Rantanen T et al. The impact of fibrin glue in the prevention of failure after nissen fundoplication.
30 Rantanen T et al. The effect of fundoplication on proliferative and anti-apoptotic activity of esophageal mucosa in gastroesophageal reflux disease: 4-year follow-up study.
31 Rantanen T et al. Proliferative and anti-apoptotic activity of esophageal mucosa in gastroesophageal reflux disease is not affected by fundoplication: a 4-year follow-up study.
32 Salenius J-P, Uurto I. Subclavian steal -oireyhtymä.
33 Salenius JP et al. Valtimoperäiset ääreisverenkierron häiriöt.
34 Shalaby A et al. Aquaporin-7 expression during coronary artery bypass grafting with Diazoxide.
35 Siltanen S et al. Contribution of ARLTS1 Cys148Arg (T442C) variant with prostate cancer risk and ARLTS1 function in prostate cancer cells.
36 Smith MR et al. Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer.
37 Suominen V. Onko diabeetikon jalkojen verenkierto riittävä.
38 Tammela T. Seulonnalla voidaan vähentää eturauhassyövän aiheuttamia kuolemia.
39 Tammela T. Virtsasuihkun heikkous ja Virtsaumpi.
40 Tammela T. Akuutti bakteeriperäinen eturauhastulehdus.
41 Tammela T. Eturauhasen liikakasvu.
42 Tammela T. Virtsarakon katetrointi ja subrapubinen kystostomia.
43 Tammela T. Krooninen eturauhastulehdus.
44 Tikkinen KAO et al. Lower urinary tract symptoms in adults treated for posterior urethral valves in childhood: matched cohort study.
45 Tolonen TT et al. Routine dual-color immunostaining with a 3-antibody cocktail improves the detection of small cancers in prostate needle biopsies.
46 Tolonen TT et al. Overall and worst gleason scores are equally good predictors of prostate cancer progression.
47 Tolonen TT et al. Histopathological variables and biomarkers enhancer of zeste homologue 2, Ki-67 and minichromosome maintenance protein 7 as prognosticators in primarily endocrine-treated prostate cancer.
48 Turpeinen H et al. Proprotein convertases in human atherosclerotic plaques: the overexpression of FURIN and its substrate cytokines BAFF and APRIL.
49 Turunen U, Jussila A. Krooniset tulehdukselliset suolistosairaudet.
50 Tähtinen RM et al. Smoking and bladder symptoms in women.
51 Vaarala M et al. Kastraation luustovaikutukset eturauhassyöpäpotilailla.
52 Vaarala M et al. Virtaa virtsaamiseen, watteja valumiseen.
53 Vaarala MH et al. Sacral neuromodulation in urological indications: the Finnish experience.
54 Vaughan CP et al. The Prevalence of Clinically Meaningful Overactive Bladder: Bother and Quality of Life Results from the Population-Based FINNO Study.
55 Venermo MA et al. EVAR may reduce the risk of aneurysm rupture despite persisting type ia endoleaks.
56 Wahlfors T et al. Identification of an aggressive prostate cancer predisposing variant at 11q13.

Julkaisutietokanta 21.9.2012 Publications Data Base 21.9.2012